Last Update: June 28, 2016
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
| |
Random lopinavir concentrations predict resistance on
lopinavir-based antiretroviral therapy.
Court R, Gordon M, Cohen K, Stewart A,
et
al
Int J Antimicrob Agents.
2016 Jun 9.
Abstract
Lopinavir Resistance Classification with Imbalanced Data
Using Probabilistic Neural Networks.
Raposo LM, Arruda MB, de Brindeiro RM, Nobre FF.
J Med Syst. 2016 Mar;40(3):69.
Abstract
FULL-TEXT ARTICLE
Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance
Profiles in Different HIV-1 Subtypes.
Grossman Z, Schapiro JM, Levy I, Elbirt D, et al
PLoS One.
2014 Jan 27;9(1):e86239.
Paper
Structural modifications induced by specific HIV-1
protease-compensatory mutations have an impact on the virological response to a
first-line lopinavir/ritonavir-containing regimen.
Alteri C, Artese A,
Beheydt G, et al
J Antimicrob Chemother.
2013 May 17
Abstract
Impact of lopinavir/ritonavir use on antiretroviral resistance in
recent clinical practice.
Lambert-Niclot S, Masquelier B, Cohen
Codar I, et al
J Antimicrob Chemother. 2012 Jun 25.
Abstract |
Frequency and patterns of protease gene resistance mutations in
HIV-infected patients treated with
lopinavir/ritonavir as their first protease inhibitor.
Barber TJ, Harrison L, Asboe D,
et al
J Antimicrob Chemother.
2012 Jan 17
Abstract
FULL-TEXT ARTICLE
Can Linear Regression Modeling Help Clinicians in the Interpretation of
Genotypic Resistance Data? An Application to Derive a Lopinavir-Score.
Cozzi-Lepri A, Prosperi MC, Kjær J, et al
PLoS One.
2011;6(11):e25665.
Paper
Lopinavir/ritonavir resistance in patients infected with HIV-1:
two divergent resistance pathways?
Champenois K, Baras A, Choisy P,
et al
J Med Virol. 2011 Jul 13.
Abstract
Genotypic Resistance at Viral Rebound among Patients Who Received
Lopinavir/ritonavir-
or Efavirenz-Based First Antiretroviral Therapy in South Africa.
Dlamini JN, Hu Z, Ledwaba J, Morris L
J Acquir Immune Defic Syndr.
2011 Jun 18.
Abstract
Protease Inhibitors Resistance Analysis in the MONARK Trial Comparing First
Line Lopinavir/ritonavir
Monotherapy to Lopinavir/ritonavir plus Zidovudine and Lamivudine triple
therapy.
Delaugerre C, Flandre P, Chaix ML, et al
Antimicrob Agents Chemother. 2009 May 18
Abstract
|
Enzymatic and Structural Analysis of the I47A Mutation Contributing to the
Reduced Susceptibility
to HIV Protease Inhibitor Lopinavir.
Grantz Saskova K, Kozisek M, et al
Protein Sci.
2008 Jun 17.
Abstract
|
Characterization of resistant HIV variants generated by
in vitro passage with
lopinavir/ritonavir.
Mo H, Lu L, Dekhtyar T, Stewart KD, et al
Antiviral Res. 2003 Aug;59(3):173-80
Abstract
|
| |
New patterns of HIV-1 resistance during HAART.
Fumero E, Podzamczer D.
Clin Microbiol Infect. 2003 Nov;9(11):1077-84.
Abstract
FULL-TEXT ARTICLE
Improving lopinavir genotype algorithm through phenotype
correlations:
novel mutation patterns and amprenavir cross-resistance.
Parkin NT, Chappey C, Petropoulos CJ
AIDS 2003 May 2;17(7):955-61
Paper
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and
reduced
replication capacity.
Prado JG, Wrin T, Beauchaine J, et al.
AIDS 2002 May 3;16(7):1009-17
Abstract
Genotypic and phenotypic cross-resistance patterns
to lopinavir and
amprenavir
in protease inhibitor-experienced patients
with
HIV viremia.
Paulsen D, Liao Q, Fusco G, St Clair M, et al.
AIDS Res Hum Retroviruses 2002 Sep 20;18(14):1011-9
Abstract |
|
|
KLS
Main Page
KLS
Journal Main Page
